Literature DB >> 10792371

Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.

E Louis1, C Ribbens, A Godon, D Franchimont, D De Groote, N Hardy, J Boniver, J Belaiche, M Malaise.   

Abstract

Inflammatory bowel diseases (IBD) are characterized by a sustained inflammatory cascade that gives rise to the release of mediators capable of degrading and modifying bowel wall structure. Our aims were (i) to measure the production of matrix metalloproteinase-3 (MMP-3), and its tissue inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1), by inflamed and uninflamed colonic mucosa in IBD, and (ii) to correlate their production with that of proinflammatory cytokines and the anti-inflammatory cytokine, IL-10. Thirty-eight patients with IBD, including 25 with Crohn's disease and 13 with ulcerative colitis, were included. Ten controls were also studied. Biopsies were taken from inflamed and uninflamed regions and inflammation was graded both macroscopically and histologically. Organ cultures were performed for 18 h. Tumour necrosis factor-alpha (TNF-alpha), IL-6, IL-1beta, IL-10, MMP-3 and TIMP-1 concentrations were measured using specific immunoassays. The production of both MMP-3 and the TIMP-1 were either undetectable or below the sensitivity of our immunoassay in the vast majority of uninflamed samples either from controls or from those with Crohn's disease or ulcerative colitis. In inflamed mucosa, the production of these mediators increased significantly both in Crohn's disease (P < 0.01 and 0.001, respectively) and ulcerative colitis (P < 0.001 and 0.001, respectively). Mediator production in both cases was significantly correlated with the production of proinflammatory cytokines and IL-10, as well as with the degree of macroscopic and microscopic inflammation. Inflamed mucosa of both Crohn's disease and ulcerative colitis show increased production of both MMP-3 and its tissue inhibitor, which correlates very well with production of IL-1beta, IL-6, TNF-alpha and IL-10.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792371      PMCID: PMC1905637          DOI: 10.1046/j.1365-2249.2000.01227.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2.

Authors:  E W Howard; E C Bullen; M J Banda
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

2.  Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease.

Authors:  C Stevens; G Walz; C Singaram; M L Lipman; B Zanker; A Muggia; D Antonioli; M A Peppercorn; T B Strom
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

3.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease.

Authors:  M D Baugh; M J Perry; A P Hollander; D R Davies; S S Cross; A J Lobo; C J Taylor; G S Evans
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA).

Authors:  M Lotz; P A Guerne
Journal:  J Biol Chem       Date:  1991-02-05       Impact factor: 5.157

5.  Microscopic activity in ulcerative colitis: what does it mean?

Authors:  S A Riley; V Mani; M J Goodman; S Dutt; M E Herd
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

6.  Use of coculture of colonic mucosal biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease.

Authors:  T D Wardle; L Hall; L A Turnberg
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

7.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

Authors:  W R Best; J M Becktel; J W Singleton
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

8.  Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts.

Authors:  A Ito; Y Itoh; Y Sasaguri; M Morimatsu; Y Mori
Journal:  Arthritis Rheum       Date:  1992-10

9.  Human alveolar macrophages secrete an inhibitor of metalloproteinase elastase.

Authors:  R J Albin; R M Senior; H G Welgus; N L Connolly; E J Campbell
Journal:  Am Rev Respir Dis       Date:  1987-06

Review 10.  Type IV collagenases in tumor invasion and metastasis.

Authors:  W G Stetler-Stevenson
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

View more
  40 in total

Review 1.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 2.  Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response.

Authors:  Akira Andoh; Shigeki Bamba; Yoshihide Fujiyama; Mairi Brittan; Nicholas A Wright
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  Expression of matrix metalloproteinases and tissue inhibitor metalloproteinases increases in X-irradiated rat ileum despite the disappearance of CD8a T cells.

Authors:  Carine Strup-Perrot; Marie-Catherine Vozenin-Brotons; Marie Vandamme; Christine Linard; Denis Mathé
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

Review 4.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

5.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

Authors:  M T Salmela; T T MacDonald; D Black; B Irvine; T Zhuma; U Saarialho-Kere; S L F Pender
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 6.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

7.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.

Authors:  Alicja Wiercinska-Drapalo; Jerzy Jaroszewicz; Robert Flisiak; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  Effect of infliximab on small bowel stenoses in patients with Crohn's disease.

Authors:  Nadia Pallotta; Fausto Barberani; Naima-Abdulkadir Hassan; Danila Guagnozzi; Giuseppina Vincoli; Enrico Corazziari
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

10.  High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD.

Authors:  Alberto J León; Emma Gómez; Jose A Garrote; David Bernardo; Asterio Barrera; Jose L Marcos; Luis Fernández-Salazar; Benito Velayos; Alfredo Blanco-Quirós; Eduardo Arranz
Journal:  Mediators Inflamm       Date:  2009-07-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.